


CLAIMS

1. A compound of formula (I):



wherein:

p is 0, 1, 2, 3 or 4;

- 10 each R¹ is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, -OR⁷, -OAY, -OR¹⁰AY, -OHet, -OR¹⁰Het, -C(O)R⁹, -C(O)AY, -C(O)Het, -CO₂R⁹, -C(O)NR⁷R⁸, -C(O)NR⁷AY, -C(O)NHR¹⁰AY, -C(O)NHR¹⁰Het, -C(S)NR⁹R¹¹, -C(NH)NR⁷R⁸, -C(NH)NR⁷AY, -S(O)_nR⁹, -S(O)_nAY, -S(O)_nHet, -S(O)₂NR⁷R⁸, -S(O)₂NR⁷AY, -NR⁷R⁸, -NR⁷AY, -NHHet, -NHR¹⁰AY, -NHR¹⁰Het, -R¹⁰cycloalkyl, -R¹⁰AY, -R¹⁰Het, -R¹⁰O-C(O)R⁹, -R¹⁰O-C(O)AY, -R¹⁰O-C(O)Het, -R¹⁰O-S(O)_nR⁹, -R¹⁰OR⁹, -R¹⁰C(O)R⁹, -R¹⁰CO₂R⁹, -R¹⁰C(O)NR⁹R¹¹, -R¹⁰C(O)NR⁷AY, -R¹⁰C(O)NHR¹⁰Het, -R¹⁰C(S)NR⁹R¹¹, -R¹⁰C(NH)NR⁹R¹¹, -R¹⁰SO_nR⁹, -R¹⁰SO₂NR⁹R¹¹, -R¹⁰SO₂NHCOR⁹, -R¹⁰NR⁷R⁸, -R¹⁰NR⁷AY, -R¹⁰NHC(NH)NR⁹R¹¹, cyano, nitro and azido; or
- 20 two adjacent R¹ groups together with the atoms to which they are bonded form a C₅₋₆cycloalkyl or a 5 or 6-membered heterocyclic ring containing 1 or 2 heteroatoms;
- each R⁷ and R⁸ are the same or different and are independently selected from
- 25 the group consisting of H, alkyl, alkenyl, cycloalkyl, cycloalkenyl, -C(O)R⁹, -CO₂R⁹, -C(O)NR⁹R¹¹, -C(S)NR⁹R¹¹, -C(NH)NR⁹R¹¹, -SO₂R¹⁰, -SO₂NR⁹R¹¹, -R¹⁰cycloalkyl, -R¹⁰OR⁹, -R¹⁰C(O)R⁹, -R¹⁰CO₂R⁹, -R¹⁰C(O)NR⁹R¹¹, -R¹⁰C(S)NR⁹R¹¹, -R¹⁰C(NH)NR⁹R¹¹, -R¹⁰SO₂R¹⁰, -R¹⁰SO₂NR⁹R¹¹, -R¹⁰SO₂NHCOR⁹, -R¹⁰NR⁹R¹¹, -R¹⁰NHCOR⁹, -R¹⁰NHSO₂R⁹ and -R¹⁰NHC(NH)NR⁹R¹¹;
- 30

each R^9 and R^{11} are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, $-R^{10}$ cycloalkyl, $-R^{10}OH$, $-R^{10}(OR^{10})_w$ where w is 1-10, and $-R^{10}NR^{10}R^{10}$;

each R^{10} is the same or different and is independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl;

Ay is aryl;

Het is a 5- or 6-membered heterocyclic or heteroaryl group;

R^2 is selected from the group consisting of halo, alkyl, alkenyl, cycloalkyl, cycloalkenyl,

Ay, Het, $-OR^7$, $-OAY$, $-OHet$, $-OR^{10}Het$, $-S(O)_nR^9$, $-S(O)_nAy$, $-S(O)_nNR^7R^8$,

$-S(O)_nHet$, $-NR^7R^8$, $-NHHet$, $-NHR^{10}Ay$, $-NHR^{10}Het$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7Ay$;

n is 0, 1 or 2;

Y is N or CH;

R^3 and R^4 are the same or different and are each independently selected from the

group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ay, Het, $-OR^7$, $-OAY$,

$-C(O)R^7$, $-C(O)AY$, $-CO_2R^7$, $-CO_2AY$, $-SO_2NHR^9$, $-NR^7R^8$, $-NR^7Ay$, $-NHHet$,

$-NHR^{10}Het$, $-R^{10}$ cycloalkyl, $-R^{10}OR^7$, $-R^{10}OAY$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7Ay$;

R^5 is selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl,

cycloalkyl, cycloalkenyl, $-OR^7$, $-OAY$, $-OHet$, $-OR^{10}Ay$, $-OR^{10}Het$, $-C(O)R^9$,

$-C(O)AY$, $-C(O)Het$, $-CO_2R^9$, $-C(O)NR^7R^8$, $-C(O)NR^7Ay$, $-C(O)NHR^{10}Het$, $-CH(OR^9)_2$,

$-CH(OR^9)-R^{10}$, $-CH(OR^9)-AY$, $-C(S)NR^9R^{11}$, $-C(NH)NR^7R^8$, $-C(NH)NR^7Ay$, $-S(O)_nR^9$,

$-S(O)_2NR^7R^8$, $-S(O)_2NR^7Ay$, $-NR^7R^8$, $-NR^7Ay$, $-NHHet$, $-NHR^{10}Ay$, $-NHR^{10}Het$,

$-R^{10}$ cycloalkyl, $-R^{10}Ay$, $-R^{10}Het$, $-R^{10}OR^9$, $-R^{10}C(O)R^9$, $-R^{10}C(O)AY$, $-R^{10}C(O)Het$,

$-R^{10}CO_2R^9$, $-R^{10}C(O)NR^9R^{11}$, $-R^{10}C(O)NR^7Ay$, $-R^{10}C(O)NHR^{10}Het$, $-R^{10}CH(OR^9)-R^{10}$;

$-R^{10}CH(OR^9)-AY$, $-R^{10}C(S)NR^9R^{11}$, $-R^{10}C(NH)NR^9R^{11}$, $-R^{10}SO_nR^9$, $-R^{10}SO_2NR^9R^{11}$,

$-R^{10}SO_2NHCOR^9$, $-R^{10}NR^7R^8$, $-R^{10}NR^7Ay$, $-R^{10}NHC(NH)NR^9R^{11}$, cyano, nitro and

azido; or

wherein when Y is CH, R^3 is not $-NR^7Ay$;

or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

2. The compound according to claim 1 wherein each R¹ is the same or different and is independently selected from the group consisting of halo, alkyl, cycloalkyl, Ay, Het, -OR⁷, -C(O)R⁹, -C(O)Het, -CO₂R⁹, -C(O)NR⁷R⁸, -C(O)NR⁷Ay, -C(O)NHR¹⁰Het, -S(O)_nR⁹, -S(O)₂NR⁷R⁸, -S(O)₂NR⁷Ay, -NR⁷R⁸, -NR⁷Ay, -NHHet, -NHR¹⁰Ay, -NHR¹⁰Het, -R¹⁰cycloalkyl, -R¹⁰Het, -R¹⁰OR⁹, -R¹⁰C(O)NR⁷Ay, -R¹⁰SO₂NHCOR⁹, -R¹⁰NR⁷R⁸, -R¹⁰NR⁷Ay, cyano, nitro and azido.
3. The compound according to claim 1 wherein each R¹ is the same or different and is independently selected from the group consisting of halo, Ay, Het, -NR⁷R⁸ and -NR⁷Ay.
4. The compound according to any of claims 1-3 wherein p is 0 or 1.
5. The compound according to any of claims 1-4 wherein R² is selected from the group consisting of halo, alkenyl, cycloalkyl, cycloalkenyl, Ay, Het, -OR⁷, -OAY, -OHet, -OR¹⁰Het, -S(O)_nR⁹, -NR⁷R⁸, -NHHet, -NHR¹⁰Het, -R¹⁰NR⁷R⁸ and -R¹⁰NR⁷Ay.
6. The compound according to any of claims 1-4 wherein R² is -NR⁷R⁸.
7. The compound according to any of claims 1-6 wherein Y is N.
8. The compound according to any of claims 1-6 wherein Y is CH.
9. The compound according to any of claims 1-8 wherein R³ and R⁴ are the same or different and are each independently selected from the group consisting of H, halo, alkyl, Ay, -OR⁷, -CO₂R⁷, -NR⁷R⁸, -R¹⁰OR⁷ and -R¹⁰NR⁷R⁸.
10. The compound according to any of claims 1-9 wherein R³ and R⁴ are both H.
11. The compound according to any of claims 1-10 wherein R⁵ is selected from the group consisting of halo, alkyl, cycloalkyl, -OR⁷, -C(O)R⁹, -C(O)Ay, -C(O)Het,

-CH(OR⁹)-R¹⁰, -CH(OR⁹)-Ay, -S(O)_nR⁹, -S(O)₂NR⁷R⁸, -NR⁷R⁸, -NR⁷Ay, -R¹⁰cycloalkyl, -R¹⁰Ay, -R¹⁰Het, -R¹⁰OR⁹, -R¹⁰C(O)R⁹, -R¹⁰SO₂NR⁹R¹¹ and -R¹⁰NR⁷R⁸.

12. The compound according to any of claims 1-10, wherein R⁵ is selected from the group consisting of alkyl, -C(O)Ay, -CH(OR⁹)-Ay, -R¹⁰cycloalkyl, -R¹⁰Ay, -R¹⁰OR⁹ and -R¹⁰NR⁷R⁸.

13. A compound selected from the group consisting of:

3-(2-Fluoropyridin-4-yl)-2-propylpyrazolo[1,5-*a*]pyridine;

10 *N*-Cyclopentyl-4-(2-propylpyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-amine;

7-Chloro-3-(2-fluoropyridin-4-yl)-2-propylpyrazolo[1,5-*a*]pyridine;

N-Cyclopentyl-3-[2-(cyclopentylamino)pyridin-4-yl]-2-propylpyrazolo[1,5-*a*]pyridin-7-amine;

2-Isobutyl-3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-*a*]pyridine;

15 2-Isobutyl-3-[2-(methylsulfinyl)pyrimidin-4-yl]pyrazolo[1,5-*a*]pyridine;

N-Cyclopentyl-4-(2-isobutylpyrazolo[1,5-*a*]pyridin-3-yl)pyrimidin-2-amine;

N-Cyclopentyl-4-[2-isobutyl-7-(methylthio)pyrazolo[1,5-*a*]pyridin-3-yl]pyrimidin-2-amine;

20 *N*-Cyclopentyl-4-[2-isobutyl-7-(methylsulfinyl)pyrazolo[1,5-*a*]pyridin-3-yl]pyrimidin-2-amine;

N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-isobutylpyrazolo[1,5-*a*]pyridin-7-amine;

2-(Diethoxymethyl)-3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-*a*]pyridine;

3-[2-(Methylthio)pyrimidin-4-yl]pyrazolo[1,5-*a*]pyridine-2-carbaldehyde;

25 {3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-*a*]pyridin-2-yl}(phenyl)methanol;

{3-[2-(Cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-*a*]pyridin-2-yl}(phenyl)methanol;

{3-[2-(Cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-*a*]pyridin-2-yl}(phenyl)methanone;

30 {7-(Cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-*a*]pyridin-2-yl}(phenyl)methanone;

- 4-(2-Benzylpyrazolo[1,5-*a*]pyridin-3-yl)-*N*-cyclopentyl-2-pyrimidinamine;
4-(2-Benzyl-7-chloropyrazolo[1,5-*a*]pyridin-3-yl)-*N*-cyclopentyl-2-pyrimidinamine;
N-{4-[2-Benzyl-7-(cyclopentylamino)pyrazolo[1,5-*a*]pyridin-3-yl]-2-pyrimidinyl}-*N*-
cyclopentylamine;
5 *N*-Cyclopentyl-4-[2-(methoxymethyl)pyrazolo[1,5-*a*]pyridin-3-yl]-2-pyrimidinamine;
N-Cyclopentyl-4-[2-(methoxymethyl)-7-(methylsulfanyl)pyrazolo[1,5-*a*]pyridin-3-yl]-
2-pyrimidinamine;
N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-
(methoxymethyl)pyrazolo[1,5-*a*]pyridin-7-amine;
10 *N*-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(1-pyrrolidinyl)propyl]-
pyrazolo[1,5-*a*]pyridin-7-amine;
N-({3-[2-(Methylsulfanyl)-4-pyrimidinyl]pyrazolo[1,5-*a*]pyridin-2-yl}methyl)-2-
propanamine;
N-Cyclopentyl-4-{2-[(isopropylamino)methyl]pyrazolo[1,5-*a*]pyridin-3-yl}-2-
15 pyrimidinamine;
N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[(isopropylamino)methyl]-
pyrazolo[1,5-*a*]pyridin-7-amine;
4-{7-Chloro-2-[3-(isopropylamino)propyl]pyrazolo[1,5-*a*]pyridin-3-yl}-*N*-
cyclopentyl-2-pyrimidinamine;
20 *N*-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(isopropylamino)propyl]-
pyrazolo[1,5-*a*]pyridin-7-amine;
4-{7-Chloro-2-[(2-methoxyethoxy)methyl]pyrazolo[1,5-*a*]pyridin-3-yl}-*N*-
cyclopentyl-2-pyrimidinamine;
3-[2-(Cyclopentylamino)-4-pyrimidinyl]-2-[(2-methoxyethoxy)methyl]-*N*-(2-
25 methoxyethyl)pyrazolo[1,5-*a*]pyridin-7-amine;
N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[(2-methoxyethoxy)-
methyl]pyrazolo[1,5-*a*]pyridin-7-amine;
N-Cyclopentyl-4-(2-isopropylpyrazolo[1,5-*a*]pyridin-3-yl)pyrimidin-2-amine;
N-Cyclo

N-Cyclopentyl-4-(2-cyclopropylpyrazolo[1,5-*a*]pyridin-3-yl)pyrimidin-2-amine; and
N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-cyclopropylpyrazolo[1,5-*a*]pyridin-7-amine;

or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

14. A pharmaceutical composition comprising a compound according to any of claims 1-13.

15. The pharmaceutical composition according to claim 14 further comprising a pharmaceutically acceptable carrier or diluent.

16. The pharmaceutical composition according to any of claims 14 or 15, further comprising an antiviral agent selected from the group consisting of aciclovir and valaciclovir or a pharmaceutically acceptable salt thereof.


17. A method for the prophylaxis or treatment of a herpes viral infection in an animal, said method comprising administering to the animal a therapeutically effective amount of a compound according to any of claims 1-13.

18. The method according to claim 17 wherein said herpes viral infection is selected from the group consisting of herpes simplex virus 1, herpes simplex virus 2, cytomegalovirus, Epstein Barr virus, varicella zoster virus, human herpes virus 6, human herpes virus 7, and human herpes virus 8.

19. A method for the prophylaxis or treatment of a condition or disease associated with a herpes viral infection in an animal, comprising administering to the animal a therapeutically effective amount of a compound according to any of claims 1-13.


20. A process for preparing a compound according to any of claims 1-13 comprising the steps of:

a) coupling a compound of formula (II):




wherein X is chloro, bromo, iodo or triflate;

10 to a terminal alkyne of formula (III):




to prepare a compound of formula (IV):



and

b) reacting an *N*-amino pyridinium salt of formula (V):



wherein Z⁻ is a counterion;

25 with the compound of the formula (IV) to prepare a compound of formula (I).

21. The process according to claim 20 further comprising the step of converting the compound of formula (I) to a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

22. The process according to claim 20 further comprising the step of converting the compound of formula (I) or a pharmaceutically acceptable salt, solvate or

physiologically functional derivative thereof to another compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

- 5 23. A compound according to any of Claims 1-13 for use in therapy.
24. A compound according to any of Claims 1-13, for use in the prophylaxis or treatment of a herpes viral infection in an animal.
- 10 25. A compound according to any of Claims 1-13, for use in the prophylaxis or treatment of a condition or disease associated with a herpes viral infection in an animal.
- 15 26. The use of a compound according to any of claims 1-13 for the preparation of a medicament for the prophylaxis or treatment of a herpes viral infection in an animal.
- 20 27. The use of a compound according to any of claims 1-13 for the preparation of a medicament for the prophylaxis or treatment of a condition or disease associated with a herpes viral infection in an animal.
28. A pharmaceutical composition comprising a compound according to any of claims 1-13 for use in the prophylaxis or treatment of a herpes viral infection in an animal.
- 